Clinical Trial Results:
Estudio de fase II, aleatorizado, doble ciego de exemestano +/- MM-121 en mujeres posmenopáusicas con cáncer de mama Her2 negativo localmente avanzado o metastásico, con receptores de estrógeno positivo (ER+) y/o receptores de progesterona positivos (RP+)_______A Randomized, Double-Blind Phase 2 trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+), Her2 negative Breast Cancer
Summary
|
|
EudraCT number |
2010-020395-28 |
Trial protocol |
ES DE DK |
Global completion date |
13 May 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jul 2019
|
First version publication date |
06 Jul 2019
|
Other versions |
|
Summary report(s) |
MM-121-02-02-03 Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.